Hexagon Composites ASA
22.2.2021 07:14:33 CET | Globenewswire | Press release
On 18 February 2021, Flakk Gruppen AS purchased 100,000 shares in Hexagon Composites ASA at a price of NOK 58.9124 per share. Flakk Gruppen AS is a company controlled by Knut Flakk, Chairman of Hexagon Composites ASA.
After the transaction Flakk Gruppen AS holds 3,853,721 shares. The total holding of Knut Flakk and his close associates, is 29,484,969 shares in Hexagon Composites ASA.
For more information:
Hiva Ghiri, VP Investor Relations, Hexagon Composites
Telephone: +47 958 66 790 | hiva.ghiri@hexagongroup.com
About Hexagon Composites
Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range of mobility, industrial and consumer applications.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
